M38-A Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi

51 Pages·2002·0.53 MB·English

M38-A Replaces M38-P
Vol. 22 No. 16 Vol. 18 No. 3
Reference Method for Broth Dilution Antifungal Susceptibility Testing
of Filamentous Fungi; Approved Standard

This document addresses the selection of antifungal agents, preparation of antifungal stock solutions and
dilutions for testing implementation and interpretation of test procedures, and quality control
requirements for susceptibility testing of filamentous fungi (moulds) that cause invasive fungal infections.
A standard for global application developed through the NCCLS consensus process.
NCCLS...
Serving the World’s Medical Science Community Through Voluntary Consensus

NCCLS is an international, interdisciplinary, nonprofit, the need for field evaluation or data collection, documents
standards-developing, and educational organization that may also be made available for review at an intermediate
promotes the development and use of voluntary (i.e., “tentative”) consensus level.
consensus standards and guidelines within the healthcare
Proposed An NCCLS consensus document undergoes the
community. It is recognized worldwide for the
first stage of review by the healthcare community as a
application of its unique consensus process in the
proposed standard or guideline. The document should
development of standards and guidelines for patient
receive a wide and thorough technical review, including an
testing and related healthcare issues. NCCLS is based on
overall review of its scope, approach, and utility, and a line-
the principle that consensus is an effective and cost-
by-line review of its technical and editorial content.
effective way to improve patient testing and healthcare
services. Tentative A tentative standard or guideline is made
available for review and comment only when a
In addition to developing and promoting the use of
recommended method has a well-defined need for a field
voluntary consensus standards and guidelines, NCCLS
evaluation or when a recommended protocol requires that
provides an open and unbiased forum to address critical
specific data be collected. It should be reviewed to ensure its
issues affecting the quality of patient testing and health
utility.
care.
Approved An approved standard or guideline has achieved
PUBLICATIONS
consensus within the healthcare community. It should be
An NCCLS document is published as a standard, reviewed to assess the utility of the final document, to
guideline, or committee report. ensure attainment of consensus (i.e., that comments on
earlier versions have been satisfactorily addressed), and to
Standard A document developed through the consensus
identify the need for additional consensus documents.
process that clearly identifies specific, essential
requirements for materials, methods, or practices for use NCCLS standards and guidelines represent a consensus
in an unmodified form. A standard may, in addition, opinion on good practices and reflect the substantial
contain discretionary elements, which are clearly agreement by materially affected, competent, and interested
identified. parties obtained by following NCCLS’s established
consensus procedures. Provisions in NCCLS standards and
Guideline A document developed through the
guidelines may be more or less stringent than applicable
consensus process describing criteria for a general
regulations. Consequently, conformance to this voluntary
operating practice, procedure, or material for voluntary
consensus document does not relieve the user of
use. A guideline may be used as written or modified by
responsibility for compliance with applicable regulations.
the user to fit specific needs.
COMMENTS
Report A document that has not been subjected to
consensus review and is released by the Board of The comments of users are essential to the consensus
Directors. process. Anyone may submit a comment, and all comments
are addressed, according to the consensus process, by the
CONSENSUS PROCESS
NCCLS committee that wrote the document. All comments,
The NCCLS voluntary consensus process is a protocol including those that result in a change to the document when
establishing formal criteria for: published at the next consensus level and those that do not
result in a change, are responded to by the committee in an
• the authorization of a project
appendix to the document. Readers are strongly encouraged
• the development and open review of documents to comment in any form and at any time on any NCCLS
document. Address comments to the NCCLS Executive
• the revision of documents in response to comments Offices, 940 West Valley Road, Suite 1400, Wayne, PA
by users 19087, USA.
• the acceptance of a document as a consensus VOLUNTEER PARTICIPATION
standard or guideline.
Healthcare professionals in all specialties are urged to
Most NCCLS documents are subject to two levels of volunteer for participation in NCCLS projects. Please
consensus—“proposed” and “approved.” Depending on contact the NCCLS Executive Offices for additional
information on committee participation.
Volume 22 M38-A

Reference Method for Broth Dilution Antifungal Susceptibility Testing
of Filamentous Fungi; Approved Standard

Abstract

NCCLS document M38-A—Reference Method for Broth Dilution Antifungal Susceptibility Testing of
Filamentous Fungi; Approved Standard describes a method for testing the susceptibility of filamentous
fungi (moulds) that cause invasive fungal infections, including Aspergillus species, Fusarium species,
Rhizopus arrhizus, Pseudallescheria boydii (Scedosporium apiospermum), and Sporothrix schenckii and
other opportunistic pathogenic moulds to antifungal agents. Selection of antifungal agents, preparation of
antifungal stock solutions and dilutions for testing, implementation, and interpretation of test procedures,
and the purpose and implementation of quality control procedures are discussed. A careful examination of
the responsibilities of the manufacturer and the user in quality control is also presented.

NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi;
Approved Standard. NCCLS document M38-A (ISBN 1-56238-470-8). NCCLS, 940 West Valley Road,
Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.

THE NCCLS consensus process, which is the mechanism for moving a document through two or more
levels of review by the healthcare community, is an ongoing process. Users should expect revised
editions of any given document. Because rapid changes in technology may affect the procedures,
methods, and protocols in a standard or guideline, users should replace outdated editions with the
current editions of NCCLS documents. Current editions are listed in the NCCLS Catalog, which is
distributed to member organizations, and to nonmembers on request. If your organization is not a
member and would like to become one, and to request a copy of the NCCLS Catalog, contact the
NCCLS Executive Offices. Telephone: [phone]; Fax: [phone]; E-Mail: [email protected];
Website: www.nccls.org

i
Number 16 NCCLS

ii
M38-A
ISBN 1-56238-470-8
ISSN 0273-3099
Reference Method for Broth Dilution Antifungal Susceptibility Testing
of Filamentous Fungi; Approved Standard

Volume 22 Number 16

Michael A. Pfaller, M.D., Chairholder
Vishnu Chaturvedi, Ph.D.
Ana Espinel-Ingroff, Ph.D.
Mahmoud A. Ghannoum, M.Sc., Ph.D.
Linda L. Gosey, M.T. (ASCP)
Frank C. Odds, Ph.D., FRC Path.
John H. Rex, M.D.
Michael G. Rinaldi, Ph.D.
Daniel J. Sheehan, Ph.D.
Thomas J. Walsh, M.D.
David W. Warnock, Ph.D., FRC Path.
Number 16 NCCLS

This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system,
transmitted, or made available in any form or by any means (electronic, mechanical, photocopying,
recording, or otherwise) without prior written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory
procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that
multiple copies of such reproduction shall include the following notice, be distributed without charge,
and, in no event, contain more than 20% of the document’s text.

Reproduced with permission, from NCCLS publication M38-A—Reference Method for
Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved
Standard (ISBN 1-56238-470-8). Copies of the current edition may be obtained from
NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the
exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request.
To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road,
Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright ©2002. The National Committee for Clinical Laboratory Standards.

Suggested Citation

(NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi;
Approved Standard. NCCLS document M38-A [ISBN 1-56238-470-8]. NCCLS, 940 West Valley Road,
Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.)

Proposed Standard
November 1998

Approved Standard
August 2002

ISBN 1-56238-470-8
ISSN 0273-3099
iv
Volume 22 M38-A

Committee Membership

Area Committee on Microbiology

James H. Jorgensen, Ph.D. University of Texas Health Center
Chairholder San Antonio, Texas

Mary Jane Ferraro, Ph.D., M.P.H. Massachusetts General Hospital
Vice-Chairholder Boston, Massachusetts

Subcommittee on Antifungal Susceptibility Tests

Michael A. Pfaller, M.D. University of Iowa College of Medicine
Chairholder Iowa City, Iowa

Vishnu Chaturvedi, Ph.D. New York State Department of Health
Albany, New York

Ana Espinel-Ingroff, M.S., Ph.D. Medical College of Virginia/VCU
Richmond, Virginia

Mahmoud A. Ghannoum, M.Sc., Ph.D. Center for Medical Mycology, Case Western
Reserve University and University Hospitals of
Cleveland
Cleveland, Ohio

Linda L. Gosey, M.T. (ASCP) Food and Drug Administration
Rockville, Maryland

Frank C. Odds, Ph.D., FRC Path University of Aberdeen
Scotland, United Kingdom

John H. Rex, M.D. University of Texas Health Science Ctr. at Houston
Houston, Texas

Michael G. Rinaldi, Ph.D. University of Texas Health Science Center
San Antonio, Texas

Daniel J. Sheehan, Ph.D. Pfizer Inc.
New York, New York

Thomas J. Walsh, M.D. National Cancer Institute
Bethesda, Maryland

David W. Warnock, Ph.D., FRC Path Centers for Disease Control and Prevention
Atlanta, Georgia

Advisor

Arthur L. Barry, Ph.D. Clinical Microbiology Institute
Wilsonville, Oregon

v
Number 16 NCCLS

Lois M. Schmidt, D.A. NCCLS
Staff Liaison Wayne, Pennsylvania

Tracy Ann Dooley, M.L.T. (ASCP) NCCLS
Project Manager Wayne, Pennsylvania

Patrice E. Polgar NCCLS
Editor Wayne, Pennsylvania

Donna M. Wilhelm NCCLS
Assistant Editor Wayne, Pennsylvania

vi
Volume 22 M38-A

Active Membership
(as of 1 July 2002)

Sustaining Members College of Medical Laboratory Department of Veterans Affairs
Technologists of Ontario Deutsches Institut für Normung
Abbott Laboratories College of Physicians and (DIN)
American Association for Surgeons of Saskatchewan FDA Center for Devices and
Clinical Chemistry ESCMID Radiological Health
Beckman Coulter, Inc. Fundación Bioquímica Argentina FDA Center for Veterinary
BD and Company International Association of Medical Medicine
bioMérieux, Inc. Laboratory Technologists FDA Division of Anti-Infective
CLMA International Council for Drug Products
College of American Pathologists Standardization in Haematology Iowa State Hygienic Laboratory
GlaxoSmithKline International Federation of Massachusetts Department of
Nippon Becton Dickinson Co., Ltd. Clinical Chemistry Public Health Laboratories
Ortho-Clinical Diagnostics, Inc. Italian Society of Clinical National Center of Infectious
Pfizer Inc Biochemistry and Clinical and Parasitic Diseases (Bulgaria)
Roche Diagnostics, Inc. Molecular Biology National Health Laboratory Service
Japan Society of Clinical Chemistry (South Africa)
Professional Members Japanese Committee for Clinical National Institute of Standards
Laboratory Standards and Technology
AISAR-Associazione Italiana per lo Joint Commission on Accreditation New York State Department of
Studio degli of Healthcare Organizations Health
American Academy of Family National Academy of Clinical Ohio Department of Health
Physicians Biochemistry Ontario Ministry of Health
American Association for National Association of Testing Pennsylvania Dept. of Health
Clinical Chemistry Authorities – Australia Saskatchewan Health-Provincial
American Association for National Society for Laboratory
Respiratory Care Histotechnology, Inc. Scientific Institute of Public Health;
American Chemical Society Ontario Medical Association Belgium Ministry of Social
American Medical Technologists Quality Management Program- Affairs, Public Health and the
American Public Health Association Laboratory Service Environment
American Society for Clinical RCPA Quality Assurance Programs Swedish Institute for Infectious
Laboratory Science PTY Limited Disease Control
American Society of Hematology Sociedade Brasileira de Analises Thailand Department of Medical
American Society for Microbiology Clinicas Sciences
American Type Culture Sociedade Brasileira de
Collection, Inc. Patologia Clinica Industry Members
Asociación Española Primera de Sociedad Espanola de Bioquimica
Socorros (Uruguay) Clinica y Patologia Molecular AB Biodisk
Asociacion Mexicana de Turkish Society of Microbiology Abbott Laboratories
Bioquimica Clinica A.C. Abbott Laboratories, MediSense
Assn. of Public Health Laboratories Government Members Products
Assoc. Micro. Clinici Italiani- Acrometrix Corporation
A.M.C.L.I. Association of Public Health Ammirati Regulatory Consulting
British Society for Antimicrobial Laboratories Anaerobe Systems
Chemotherapy Armed Forces Institute of Pathology Asséssor
CADIME-Camara De Instituciones BC Centre for Disease Control AstraZeneca
De Diagnostico Medico Centers for Disease Control and AstraZeneca R & D – Boston, MA
Canadian Society for Medical Prevention Aventis
Laboratory Science—Société Centers for Medicare & Medicaid Axis-Shield POC AS
Canadienne de Science de Services/CLIA Program Bayer Corporation – Elkhart, IN
Laboratoire Médical Centers for Medicare & Medicaid Bayer Corporation – Tarrytown, NY
Clinical Laboratory Management Services Bayer Corporation – West Haven,
Association Chinese Committee for Clinical CT
COLA Laboratory Standards Bayer Medical Ltd.
College of American Pathologists Commonwealth of Pennsylvania BD
Bureau of Laboratories BD Biosciences – San Jose, CA
vii
Number 16 NCCLS

BD Consumer Products General Hospital Vienna (Austria) Roche Laboratories (Div.
BD Diagnostic Systems Gen-Probe Hoffmann-La Roche Inc.)
BD Italia S.P.A. GlaxoSmithKline Sarstedt, Inc.
BD VACUTAINER Systems Greiner Bio-One Inc. SARL Laboratoire Carron (France)
Beckman Coulter, Inc. Helena Laboratories Schering Corporation
Beckman Coulter, Inc. Primary Care Home Diagnostics, Inc. Schleicher & Schuell, Inc.
Diagnostics Immunicon Corporation Second Opinion
Beckman Coulter K.K. (Japan) Instrumentation Laboratory Showa Yakuhin Kako Company,
Bio-Development SRL International Technidyne Ltd.
Bio-Inova Life Sciences Corporation Streck Laboratories, Inc.
International IntraBiotics Pharmaceuticals, Inc. SurroMed, Inc.
Bio-Inova Life Sciences North I-STAT Corporation Synermed Diagnostic Corp.
America Johnson and Johnson Pharmaceutical Sysmex Corporation (Japan)
BioMedia Laboratories Sdn Bhd Research and Development, Sysmex Corporation - Long Grove,
BioMérieux (NC) L.L.C. IL
bioMérieux, Inc. (MO) Kendall Sherwood-Davis & Geck The Clinical Microbiology Institute
Biometrology Consultants LAB-Interlink, Inc. The Toledo Hospital (OH)
Bio-Rad Laboratories, Inc. Laboratory Specialists, Inc. Theravance Inc.
Bio-Rad Laboratories, Inc. - France Labtest Diagnostica S.A. Transasia Engineers
Biotest AG LifeScan, Inc. (a Johnson & Trek Diagnostic Systems, Inc.
Blaine Healthcare Associates, Inc. Johnson Company) Versicor, Inc.
Bristol-Myers Squibb Company Lilly Research Laboratories Vetoquinol S.A.
Canadian External Quality Macemon Consultants Visible Genetics, Inc.
Assessment Laboratory Medical Device Consultants, Inc. Vysis, Inc.
Capital Management Consulting, Merck & Company, Inc. Wallac Oy
Inc. Minigrip/Zip-Pak Wyeth-Ayerst
Carl Schaper Molecular Diagnostics, Inc. Xyletech Systems, Inc.
Checkpoint Development Inc. mvi Sciences (MA) YD Consultant
Chiron Corporation Nabi YD Diagnostics (Seoul, Korea)
ChromaVision Medical Systems, Nichols Institute Diagnostics
Inc. (Div. of Quest Diagnostics, Inc.) Trade Associations
Chronolab Ag NimbleGen Systems, Inc.
Clinical Design Group Inc. Nissui Pharmaceutical Co., Ltd. AdvaMed
Clinical Laboratory Improvement Nippon Becton Dickinson Co., Ltd. Association of Medical
Consultants Norfolk Associates, Inc. Diagnostic Manufacturers
Cognigen Novartis Pharmaceuticals Japan Association Clinical
Community Medical Center (NJ) Corporation Reagents Ind. - Tokyo, Japan
Control Lab (Brazil) Ortho-Clinical Diagnostics, Inc. Medical Industry Association
Copan Diagnostics Inc. (Raritan, NJ) of Australia
Cosmetic Ingredient Review Ortho-Clinical Diagnostics, Inc.
Cubist Pharmaceuticals (Rochester, NY) Associate Active Members
Dade Behring Inc. - Deerfield, IL Oxoid Inc.
Dade Behring Inc. - Glasgow, DE Paratek Pharmaceuticals 20th Medical Group (SC)
Dade Behring Inc. - Marburg, Pfizer Inc 31st Medical Group/SGSL (APO,
Germany Pharmacia Corporation AE)
Dade Behring Inc. - Sacramento, CA Philips Medical Systems 67th CSH Wuerzburg, GE (NY)
Dade Behring Inc. - San Jose, CA Powers Consulting Services 121st General Hospital (CA)
David G. Rhoads Associates, Inc. Premier Inc. Academisch Ziekenhuis-VUB
Diagnostics Consultancy Procter & Gamble (Belgium)
Diagnostic Products Corporation Pharmaceuticals, Inc. Acadiana Medical Laboratories,
Eiken Chemical Company, Ltd. The Product Development Group LTD (LA)
Elan Pharmaceuticals QSE Consulting Adena Regional Medical Center
Electa Lab s.r.l. Quintiles, Inc. (OH)
Enterprise Analysis Corporation Radiometer America, Inc. Advocate Healthcare Lutheran
Essential Therapeutics, Inc. Radiometer Medical A/S General (IL)
EXPERTech Associates, Inc. Roche Diagnostics GmbH Akershus Central Hospital and AFA
F. Hoffman-La Roche AG Roche Diagnostics, Inc. (Norway)
Fort Dodge Animal Health Albemarle Hospital (NC)
viii